

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 10659

Table 1.--Testing Results "FORDS" Study
Dextroamphetamine Sulfate Tablets U.S.P. XVIII

[Survey Period - September 1971-January 1972]

Manufacturer	Declared potency (mg.)	Number batches sampled and analyzed	Number defective samples
American Pharmaceutical Co.	5	2	0
George N. Bell, Mfg. Chemists	5	2	0
Bolar Pharmaceutical Co.	5	4	0
	10	2	1 (a)
	15	3	0
The C. M. Bundy Co.	5	1	1 (b)
Columbia Pharmaceutical Corp.	5	1	0
	15	1	0
Don Hall Labs., Inc.	2.5	1	0
	5	1	0
	10	1	0
E. W. Heun Co.	3	1	0
	5	3	0
	10	1	0
Invenex Pharmaceuticals.....	5	1	0
	10	1	0
Kasar Labs.	5	1	0
Kirkman Labs., Inc.	5	1	0
The Lannett Co., Inc.	5	1	0
Linden Labs., Inc.	15	1	0
Mills Pharmaceuticals, Inc.	5	1	0
Philips Roxane Labs., Inc.	5	1	0
Premo Pharmaceutical Labs., Inc.	5	2	0
Rondex Labs., Inc.	5	1	0
Smith, Kline, & French Labs.	5	8	0
Stayner Corp.	5	1	0
Towne, Paulsen & Co., Inc.	5	1	0
	10	2	0
West-Ward, Inc.	5	1	0
West Coast Labs.	4	1	0
	12	1	0
The Zemmer Co.	10	2	0
Totals		52	2

(a) Defective due to subpotency (88.8% of declared), and lack of content uniformity (three tablets; 84.5%, 83.3%, and 84.8% of declared). Lot destroyed under State supervision. (b) Defective due to lack of content uniformity (two tablets; 128.6% and 116.8% of declared). Lot voluntarily removed by manufacturer from distribution channels.